Annexin Pharmaceuticals (Q1 review): Study on track - Redeye
Redeye comments on Annexin’s Q1 report and recent events and see continued good progress with the ongoing phase II study. We reiterate our valuation for now.
ANNONS
Redeye comments on Annexin’s Q1 report and recent events and see continued good progress with the ongoing phase II study. We reiterate our valuation for now.
